| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 07/20/2005 | CN1642948A Piperazinyl-, piperidinyl- and morpholinyl-derivatives as novel inhibitors of histone deacetylase |
| 07/20/2005 | CN1642912A Sulfonylamino-derivatives as novel inhibitors of histone deacetylase |
| 07/20/2005 | CN1642907A Carbonylamino-derivatives as novel inhibitors of histone deacetylase |
| 07/20/2005 | CN1642904A Salts of nateglinide |
| 07/20/2005 | CN1642578A Topical composition comprising a cyclofructan, a carrier and a drug |
| 07/20/2005 | CN1642577A Preparation comprising buprenorphine |
| 07/20/2005 | CN1642574A Remedies for glomerular diseases |
| 07/20/2005 | CN1642573A Combination of an aldosterone receptor antagonist and a fibric acid derivative |
| 07/20/2005 | CN1642569A Treatment of type I diabetes |
| 07/20/2005 | CN1642568A Methods and compositions for treating gastrointestinal toxicity induced by cytoablative therapy |
| 07/20/2005 | CN1642559A Combination comprising an HMG-CoA reductase inhibitor and an insulin secretor enhancer or an insulin sensitizer |
| 07/20/2005 | CN1642557A Combination of an aldosterone receptor antagonist and nicotinic acid or a nicotinic acid derivative |
| 07/20/2005 | CN1642556A Combination of an aldosterone receptor antagonist and a bile acid sequestering agent |
| 07/20/2005 | CN1642551A Inhibitors of histone deacetylase |
| 07/20/2005 | CN1642548A Pharmaceutical composition with combined active agents and methods for using the same |
| 07/20/2005 | CN1642547A Pharmaceutical composition and method for treating disorders of the central nervous system |
| 07/20/2005 | CN1642544A Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors |
| 07/20/2005 | CN1642536A Agents for corneal or intrastromal administration to treat or prevent disorders of the eye |
| 07/20/2005 | CN1642535A Tuberculosis treatment using pleuromutilin derivatives |
| 07/20/2005 | CN1642528A Stable salts of O-acetylsalicylic acid containing basic amino acids II |
| 07/20/2005 | CN1640495A Ophthalmological anti proliferative medicine containing sodium alginate micro gel bead and convex membrane and preparing method |
| 07/20/2005 | CN1640387A Intradermal absorbing paster and its preparing method |
| 07/20/2005 | CN1211661C Method of detection of amyloidogenic proteins |
| 07/20/2005 | CN1211375C Thiazole-derivatives |
| 07/20/2005 | CN1211164C Medium milling |
| 07/20/2005 | CN1211126C Vascular endothelial growth factor 2 |
| 07/20/2005 | CN1211089C Application of uridine phosphorylase inhibitor and composition containing the same |
| 07/20/2005 | CN1211085C Compositions having improved stability |
| 07/20/2005 | CN1211080C Method for preparing microcapsule |
| 07/20/2005 | CN1211079C Stable slow-releasing oral administration composition |
| 07/20/2005 | CN1211077C Histamine H2 antagonist effervescent composition |
| 07/20/2005 | CN1211070C Facial tissue compsn. and method of use for sequestration of nasal secretion skin irritants |
| 07/20/2005 | CN1211063C Compositions comprising organosiloxane resins for delivering oral care substances |
| 07/19/2005 | US6919432 Substances and their uses |
| 07/19/2005 | US6919425 Isolation of a cell-specific internalizing peptide that infiltrates tumor tissue for targeted drug delivery |
| 07/19/2005 | US6919424 Comprises polypeptide for, diagnosis, detection and treatment of cancer |
| 07/19/2005 | US6919377 Cyclohexylamine derivative as subtype selective NMDA receptor antagonists |
| 07/19/2005 | US6919370 Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof |
| 07/19/2005 | US6919366 Benzimidazole derivatives as modulators of IgE |
| 07/19/2005 | US6919353 Enzyme inhibitors of phosphordiesterase 4 having minimal side effects; antiinflammatory agents; antiallergens; asthma; neurodegenerative disorders; antidiabetic agents; pain; anti-tumor, -carcinogenic and -arthritic agents |
| 07/19/2005 | US6919351 Aza-and polyaza-naphthalenyl-carboxamides useful as HIV integrase inhibitors |
| 07/19/2005 | US6919350 Compositions and methods for reducing respiratory depression and attendant side effects of mu opioid compounds |
| 07/19/2005 | US6919348 1-R1- phenyl, 4-R2-phenyl substituted 1,2,3,6-tetrahydropyrimidine-2- one cold receptor agonist in a therapeutically effective amount and preferably further comprises one or more pharmaceutically active drugs such as |
| 07/19/2005 | US6919347 Antidiabetic agents; antiinflammatory agents; analgesics; antiallergens |
| 07/19/2005 | US6919345 Sulfonate substituted pyrazol pyridine derivatives |
| 07/19/2005 | US6919339 ABCA-1 elevating compounds |
| 07/19/2005 | US6919335 Heterocycles that are inhibitors of IMPDH enzyme |
| 07/19/2005 | US6919330 Formulations of drugs |
| 07/19/2005 | US6919320 Pharmaceutical compositions containing deoxyribonucleosides for wound healing |
| 07/19/2005 | US6919317 For therapy of diseases involving fungal or suspected fungal infection, for immunomodulation or immunosuppression in conditions in which fungal or suspected fungal colonisation of e.g.skin plays a role |
| 07/19/2005 | US6919310 Administering drug formulation comprising opioidergic agent and an insulin secretagogue for therapy of human suffering from one or more conditions included within Coronary Heart Disease Risk Factor Syndrome |
| 07/19/2005 | US6919072 Comprises matrix metalloproteinase (MMP) inhibitor; for promoting collagen production |
| 07/14/2005 | WO2005064332A1 Highly active lysophosphatidic acid and method of screening therewith |
| 07/14/2005 | WO2005063697A2 Substituted n-aryl amidines as selective d1 dopamine receptor antagonists for the treatment of obesity and cns disorders |
| 07/14/2005 | WO2005063302A1 Drug for preventing or treating heart diseases comprising cd9 gene |
| 07/14/2005 | WO2005063297A2 Melatonin combination therapy for improving sleep quality |
| 07/14/2005 | WO2005063296A2 Therapeutic combination for cognition enhancement and psychotic disorders |
| 07/14/2005 | WO2005063295A1 Agents for treatment of glaucomatous retinopathy and optic neuropathy |
| 07/14/2005 | WO2005063294A1 Inhibitor for the formation of ϝ-secretase complex |
| 07/14/2005 | WO2005063275A1 Methods and compositions for the prevention and treatment of inflammatory diseases or conditions |
| 07/14/2005 | WO2005063270A1 Composition comprising an aqueous extract of red vine leaves and a diuretic for the treatment of chronic venous insufficiences |
| 07/14/2005 | WO2005063269A1 Composition comprising an aqueous extract of red vine leaves and a antithrombotic agent for the treatment of chronic venous insufficiences |
| 07/14/2005 | WO2005063268A1 Composition comprising an aqueous extract of red vine leaves and a blood circulation-improving agent for the treatment of chronic venous insufficiences |
| 07/14/2005 | WO2005063266A1 Therapeutical composition for the treatment of dermatosis comprising an extract of calendula officinalis and hypericum perforatum |
| 07/14/2005 | WO2005063248A1 Modafinil combination therapy for improving sleep quality |
| 07/14/2005 | WO2005063241A1 Preventive and/or therapeutic agent for disease in which mitochondrial benzodiazepine receptor participates |
| 07/14/2005 | WO2005063235A1 Anticancer therapy-aiding composition comprising polyphenol, and ascorbic acid or the derivatives |
| 07/14/2005 | WO2005063234A2 Use of at least one effector of glutathione metabolism, together with alpha-liponic acid for the treatment of lung diseases |
| 07/14/2005 | WO2005063226A1 Compositions and methods for treating diabetes |
| 07/14/2005 | WO2005063199A1 Effervescent preparation of a basic medicinal substance |
| 07/14/2005 | WO2005063147A1 Use of alginate matrices to control cell growth |
| 07/14/2005 | WO2005062957A2 Compositions and methods for combined therapy of disease |
| 07/14/2005 | WO2005062879A2 Canine probiotic bifidobacteria pseudolongum |
| 07/14/2005 | WO2005062878A2 Canine probiotic bifidobacteria globosum |
| 07/14/2005 | WO2005062874A2 Compounds and compositions for delivering active agents |
| 07/14/2005 | WO2005062791A2 Utilization of stem cell and fibroblast combined products and nutrients in topical compositions |
| 07/14/2005 | WO2005062782A2 Non-animal product containing veterinary formulations |
| 07/14/2005 | WO2005039320A3 Composition for the activation of the immune system |
| 07/14/2005 | WO2005035514A3 Modulators of atp-binding cassette transporters containing cycloalkyl or pyranyl groups |
| 07/14/2005 | WO2004064769A3 Methods for making and using topical delivery agents |
| 07/14/2005 | WO2004047838A2 Pharmaceutical composition comprising beta-3-adrenoceptor agonists and antimuscarinic agents |
| 07/14/2005 | WO2004017923A3 Compositions and methods of therapy for cancers characterized by expression of the tumor-associated antigen mn/ca ix |
| 07/14/2005 | WO2004000016A9 Antimicrobial compositions, products and methods employing same |
| 07/14/2005 | WO2003059294A3 Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor |
| 07/14/2005 | US20050155089 Transport protein for use in identifying modulators for prevention and treatment of inflammation, cardiovascular, neurological, reproductive and developmental disorders |
| 07/14/2005 | US20050155087 Method of screening compounds |
| 07/14/2005 | US20050154165 Ph-sensitive polymer |
| 07/14/2005 | US20050154047 Exert the beneficial effects of melatonin including anti-oxidation, sedation, anesthesia, protection of organs to chemical, infectious and cardiovascular damage, and can be administered in a water-based vehicle |
| 07/14/2005 | US20050154026 Suitable for the treatment of gastric and intestinal disorders; in particular, omeprazole, rabeprazole, pantoprazole, esomeprazole |
| 07/14/2005 | US20050154014 Anticarcinogenic agents; antitumor agents treating cancer of breast, head, neck, gastrointestinal system or stomach, ovaries, bronchi, lungs or pancreas; leukemia |
| 07/14/2005 | US20050154013 Pressurised metered dose inhalers containing solutions of beta-2 agonists |
| 07/14/2005 | US20050154007 Substituted imidazo[1,2-a]pyridines such as 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-6-methoxyimidazo[1,2-a]pyridine, used as antisectory agents for prophylaxis of gastrointestinal disorders |
| 07/14/2005 | US20050153985 Methods of treating acute inflammation in animals with p38 map kinase inhibitors |
| 07/14/2005 | US20050153983 Synergistic combination of an opioid analgesic and a nsaid |
| 07/14/2005 | US20050153965 Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade |
| 07/14/2005 | US20050153953 Compositions and methods of treatment using L-type calcium channel blockers and cholinesterase inhibitors |
| 07/14/2005 | US20050153952 Methods for inhibiting sterol absorption |
| 07/14/2005 | US20050153947 administering mixture of serotonine reuptake inhibitor and corticosteroid |
| 07/14/2005 | US20050153940 Method for using potassium channel activation for delivering a medicant to an abnormal brain region and/or a malignant tumor |
| 07/14/2005 | US20050153934 Chaperone-based therapy for Niemann-Pick disease |